Perceptive Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Perceptive Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-341,239	Closed	-$5.37M	–	101
2022 Q4	$5.37M	Hold	341,239	–	–	0.15%	70
2022 Q3	$5.37M	Hold	341,239	–	–	0.16%	78
2022 Q2	$4.76M	Sell	341,239 -42,000	-11%	-$589K	0.15%	80
2022 Q1	$6.61M	Sell	383,239 -397,997	-51%	-$5.43M	0.13%	95
2021 Q4	$11.4M	Hold	781,236	–	–	0.18%	85
2021 Q3	$14.1M	Sell	781,236 -68,764	-8%	-$1.1M	0.2%	85
2021 Q2	$14.9M	Buy	850,000 +200,000	+31%	+$4.54M	0.19%	95
2021 Q1	$16.4M	Buy	+650,000	New	+$12.7M	0.21%	86
2017 Q2	–	Sell	-1,260,847	Closed	-$37.6M	–	130
2017 Q1	$37.6M	Hold	1,260,847	–	–	2.14%	11
2016 Q4	$34.2M	Buy	1,260,847 +830,847	+193%	+$21.2M	2.43%	11
2016 Q3	$11M	Buy	+430,000	New	+$9.12M	0.71%	36

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Perceptive Advisors's ACRS Position: Q1 2023 in Review

Perceptive Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 341,239 shares — an estimated $5.37M sold.

Perceptive Advisors first reported a position in ACRS in Q3 2016 and held it in 11 quarters. The position peaked at $37.6M in Q1 2017. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

Perceptive Advisors reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
Perceptive Advisors sold 341,239 Aclaris Therapeutics shares in Q1 2023, an estimated $5.37M.
Perceptive Advisors first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 11 quarters.
Perceptive Advisors's Aclaris Therapeutics position peaked at $37.6M in Q1 2017.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.